Physician profile
Amy Beth Pearson
NPI 1578524195
$2,795.14
in general payments reported to CMS, 2019-2025
27 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.34 · 2020: $83.54 · 2021: $348 · 2022: $173 · 2023: $52.30 · 2024: $847 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $488.17 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Acadia Pharmaceuticals INC | $269.50 | 2024 | Nuplazid |
| Amgen INC. | $238.24 | 2021-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $205.53 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $185.93 | 2022-2025 | |
| Abbott Laboratories | $143.94 | 2021-2024 | Amplatzer Amulet |
| Eisai INC. | $138.60 | 2024-2025 | |
| Neurelis, INC. | $133.23 | 2021-2025 | Valtoco |
| Verona Pharma, INC. | $131.13 | 2025 | Ohtuvayre |
| Pfizer INC. | $121.35 | 2021-2025 | |
| Exact Sciences Corporation | $101.17 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $98.47 | 2023-2025 | Briviact, Nayzilam |
| Glaxosmithkline, LLC. | $95.89 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Edwards Lifesciences Corporation | $83.54 | 2020 | |
| Esperion Therapeutics, INC. | $48.46 | 2021-2024 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.32 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $37.43 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $34.32 | 2025 | |
| Lilly USA, LLC | $33.53 | 2021-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.54 | 2021-2024 | |
| Viatris Specialty LLC | $31.32 | 2025 | Yupelri |
| Mylan Specialty L.P. | $25.45 | 2021 | |
| Insulet Corporation | $17.83 | 2024 | Omnipod |
| Dexcom, INC. | $15.67 | 2021 | |
| Heartflow, INC. | $14.39 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.50 | 2025 | |
| Daiichi Sankyo INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.